Accès ouvert · CC BY

DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

Article scientifique 2017 Sciences de la santé › Santé publique (OCDE 3.3) Anglais

Résumé

Influenza virus remains a significant public health threat despite innovative vaccines and antiviral drugs. A major limitation to current vaccinations and therapies against influenza virus is pathogenic diversity generated by shift and drift. A simple, cost-effective passive immunization strategy via in vivo production of cross-protective antibody molecules may augment existing vaccines and antiviral drugs in seasonal and pandemic outbreaks. We engineered synthetic plasmid DNA to encode two novel and broadly cross-protective monoclonal antibodies targeting influenza A and B. We utilized enhanced in vivo delivery of these plasmid DNA-encoded monoclonal antibody (DMAb) constructs and show that this strategy induces robust levels of functional antibodies directed against influenza A and B viruses in mouse sera. Mice receiving a single inoculation with anti-influenza A DMAb survive lethal Group 1 H1 and Group 2 H3 influenza A challenges, while inoculation with anti-influenza B DMAb yields protection against lethal Victoria and Yamagata lineage influenza B morbidity and mortality. Furthermore, these two DMAbs can be delivered coordinately resulting in exceptionally broad protection against both influenza A and B. We demonstrate this protection is similar to that achieved by conventional protein antibody delivery. DMAbs warrant further investigation as a novel immune therapy platform with distinct advantages for sustained immunoprophylaxis against influenza.

Citer ce document

Elliott, S. T. C., Kallewaard, N. L., Benjamin, E., Wachter-Rosati, L., McAuliffe, J. M., Patel, A., Smith, T. R., Schultheis, K., Park, D. H., Flingai, S., Wise, M. C., Mendoza, J., Ramos, S., Broderick, K. E., Yan, J., Humeau, L., Sardesai, N. Y., Muthumani, K., Zhu, Q., & Weiner, D. B. (2017). DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections. npj Vaccines. https://doi.org/10.1038/s41541-017-0020-x

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 27/08/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 14

Téléchargements (hors robots) : 0

Méthode de comptage